BridgeBio to Showcase ATTRibute-CM Data at ESC Congress 2025

BridgeBio Pharma will present additional open-label extension data from the ATTRibute-CM study at the European Society of Cardiology Congress 2025. The data includes results on acoramidis' effect on cardiovascular mortality, NT-proBNP, and change in NAC ATTR stage. The presentations will highlight the efficacy of Attruby in treating wild-type or variant transthyretin-mediated amyloidosis.

BridgeBio Pharma (Nasdaq: BBIO) has announced it will present additional open-label extension data from the ATTRibute-CM study at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The presentations, scheduled for August 29-31, 2025, will provide insights into the efficacy of Attruby™, a transthyretin stabilizer, in treating wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM).

The oral presentation, titled "Acoramidis Reduces Cardiovascular Mortality (CVM): Results at Month 42 from the ATTRibute-CM Open-label Extension (OLE) Study," will be presented by Kevin Alexander, M.D., of Stanford University School of Medicine, USA, on Saturday, August 30 at 1:15 pm CEST/7:15 am ET. This session will focus on the cardiovascular mortality reduction at Month 42.

Two ePosters will also be presented, one by Nitasha Sarswat, M.D., of UChicago Medicine, USA, and another by Julian Gillmore, M.D., Ph.D., of University College London's Centre for Amyloidosis, UK. The first ePoster, "Acoramidis-mediated Improvement in NT-proBNP at Month 30 Compared with Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM Study," will be presented on Sunday, August 31 at 4:15 pm CEST/10:15 am ET. The second ePoster, "Acoramidis Has a Beneficial Effect Compared with Placebo on Change from Baseline in NAC ATTR Stage at Month 30 in Patients with ATTR-CM: Results from the ATTRibute-CM Study," will be presented on Saturday, August 29 at 3:15 pm CEST/9:15 am ET.

The ATTRibute-CM study aims to evaluate the efficacy of acoramidis, the active ingredient in Attruby, in reducing cardiovascular mortality and improving NT-proBNP levels, a biomarker for heart failure. The data presented will provide valuable insights into the potential benefits of Attruby in the treatment of ATTR-CM, a progressive disease characterized by the buildup of abnormal proteins in the heart.

BridgeBio Pharma, founded in 2015, is dedicated to discovering and delivering transformative medicines for genetic diseases. The company's pipeline includes early-stage and advanced clinical trials, reflecting its commitment to applying genetic medicine to treat patients as quickly as possible. For more information, visit bridgebio.com.

References:
[1] https://www.stocktitan.net/news/BBIO/bridge-bio-to-present-additional-open-label-extension-data-from-att-oobhx6xm66jp.html